| |
 |
Editorial [Hot Topic: The Impact of Microbiota and Cytokines on Inflammatory Bowel Disease (Executive Editors: Osamu Kanauchi and Keiichi Mitsuyama)]
|
| |
|
pp.2049-2050 (2) Authors: Osamu Kanauchi, Keiichi Mitsuyama
|
| |
|
|
| |
|
The Intestinal Environment in Health and Disease – Recent Insights on the Potential of Intestinal Bacteria to Influence Human Health
|
| |
|
pp.2051-2065 (15) Authors: Sam Possemiers, Charlotte Grootaert, Joan Vermeiren, Gabriele Gross, Massimo Marzorati, Willy Verstraete, Tom Van de Wiele
|
| |
|
|
| |
|
Recent Advances in Molecular Approaches to Gut Microbiota in Inflammatory Bowel Disease
|
| |
|
pp.2066-2073 (8) Authors: Akira Andoh, Yoshimi Benno, Osamu Kanauchi, Yoshihide Fujiyama
|
| |
|
|
| |
|
The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
|
| |
|
pp.2074-2086 (13) Authors: Osamu Kanauchi, Keiichi Mitsuyama, Akira Andoh
|
| |
|
|
| |
|
Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
|
| |
|
pp.2087-2094 (8) Authors: Hiroyuki Hanai, Ken Sugimoto
|
| |
|
|
| |
|
Interleukin-6 Trans-Signaling and Colonic Cancer Associated with Inflammatory Bowel Disease
|
| |
|
pp.2095-2103 (9) Authors: Stefan Rose-John, Keiichi Mitsuyama, Satoshi Matsumoto, Wolfgang M. Thaiss, Jurgen Scheller
|
| |
|
|
| |
|
Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
|
| |
|
pp.2104-2109 (6) Authors: Jun Nishihira, Keiichi Mitsuyama
|
| |
|
|
| |
|
Recent Understanding of Leukocytapheresis (LCAP) for the Treatment of Inflammatory Bowel Disease
|
| |
|
pp.2110-2119 (10) Authors: Keiichi Mitsuyama, Hiroshi Yamasaki, Kotaro Kuwaki, Hidetoshi Takedatsu, Michio Sata
|
| |
|
|
| |
|
Developments of Indoles as Anti-HIV-1 Inhibitors
|
| |
|
pp.2120-2148 (29) Authors: Hui Xu, Min Lv
|
| |
|
|
| |
|
HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
|
| |
|
pp.2149-2168 (20) Authors: A. D. Wickenden, M. P. Maher, S. R. Chaplan
|
| |
|
|
